ENLV | Enlivex Therapeutics Ltd. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	1.1500 - 1.2300
52 Week Range	0.8100 - 4.59
Beta	1.62
Implied Volatility	561.07%
IV Rank	70.32%
Day's Volume	106,995
Average Volume	248,075
Shares Outstanding	21,989,500
Market Cap	25,947,610
Sector	Healthcare
Industry	Biotechnology
IPO Date	2014-07-31

Valuation
Profitability
Growth
Health
P/E Ratio	-1.20
Forward P/E Ratio	N/A
EPS	-0.98
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	71
Country	Israel
Website	ENLV

Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel.

ENLV's peers: PLUR, BLRX, PPBT, ARDS, HSTO, PMVP, APVO, PLX, CRVS, PHIO, RAIN, CLGN, KROS, MRUS, VCEL, IPSC, ALDX, GMDA, CKPT

*Chart delayed

Analyzing fundamentals for ENLV we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is very bad and Health is very weak. For more detailed analysis please see ENLV Fundamentals page.

Watching at ENLV technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on ENLV Technicals page.